The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Artificial intelligence (AI) is rapidly being integrated into every domain of healthcare, giving birth to a new class of tech ...

Researchers from Mass General Brigham , Harvard Medical School and Duke University School of Medicine have identified nearly ...

Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Aaron ...

Former House Speaker Nancy Pelosi's stock portfolio has taken a major hit in 2025, aligning with the broader market sell-off.

The global personal genome testing market is on a remarkable growth trajectory, projected to soar to USD 4,468 million by 2032, up from USD 1,545.5 million in 2022. This growth reflects a robust CAGR ...

In February 2025, Tempus AI, Inc. (NASDAQ:TEM) completed the acquisition of Ambry Genetics, enhancing its capabilities in genetic testing and data services. Tempus’s stock has experienced ...

The healthcare technology space is gaining enormous investors' attention these days, thanks to the rapid advancements in artificial intelligence (AI) in this niche. Companies like Tempus AI TEM are ...

The February 2025 acquisition of Ambry Genetics further expanded its genomics capabilities with a West Coast lab and enhanced inherited risk testing. Additionally, a five-year extension with ...

But the company could not build a sustainable business and many of the 15 million people who gave their genetic information to the platform are worried about where their personal data could end up.

Genetics Home Reference. Ambry Genetics. How are direct-to-consumer and medical-grade genetic tests different? U.S. National Library of Medicine. What is the cost of genetic testing, and how long does ...